Custom-Made vaccine aims to keep head and neck cancer from coming back
NCT ID NCT04183166
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tests a personalized immunotherapy called TG4050 in 80 people with newly diagnosed, advanced head and neck cancer. Participants receive the treatment after standard therapy to see if it safely delays the cancer's return. The approach targets unique mutations in each patient's tumor to boost the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aintree University Hospital NHS Fondation Trust
Liverpool, L9 7AL, United Kingdom
-
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, 15076, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Regional Universitario de Málaga - Hospital Civil
Málaga, 29010, Spain
-
Hospital Universitari Vall d Hebrón
Barcelona, 08035, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hôpital Saint André - CHU de Bordeaux
Bordeaux, 33000, France
-
Hôpital de la Timone
Marseille, 13000, France
-
IUCT Toulouse
Toulouse, 31100, France
-
Institut Català d Oncologia - Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
NHS Clatterbridge Cancer Center
Liverpool, L7 8YA, United Kingdom
Conditions
Explore the condition pages connected to this study.